Please read our COVID-19 update.

medac Pharma announce deal with Delcath Systems to market hepatic delivery system CHEMOSAT® throughout Europe

 

 

Stirling based pharmaceutical company, medac Pharma, has announced a licensing deal with Delcath Systems to market their hepatic delivery system CHEMOSAT®. Delcath Systems has licensed medac to sell and market CHEMOSAT® in the UK and all other member states of the EU, Norway, Liechtenstein and Switzerland.

With an already well established portfolio of oncology products, CHEMOSAT® provides medac Pharma with a substantial new business opportunity which strengthens and expands the company’s expertise in this specialised field.

The innovative CHEMOSAT® system has been developed to treat liver metastases and works by isolating the liver’s circulatory system, infusing the liver with the chemotherapeutic agent melphalan hydrochloride  and then filtering patient’s blood before returning it to the patient in a procedure called percutaneous hepatic perfusion (PHP). This low invasive procedure allows much higher concentration of melphalan hydrochloride  without systemic exposure thereby reducing the side-effects of the chemotherapy. With this treatment the proliferation of the tumours can at least be stopped or the tumours can even be destroyed.

Managing Director of medac Pharma, Alastair McMurray comments: “We are able to provide the organisational scale, expertise and market reach necessary to help firmly establish CHEMOSAT® in the UK and provide another treatment option for metastatic tumours of the liver, something which has historically been very difficult to treat. We already have a well-established network amongst oncology key opinion leaders and therefore we will be a well-suited partner to help with the commercialisation of CHEMOSAT® in the UK.

“We are excited to build upon the growing customer base that Delcath Systems has already established to provide patients with liver metastases a promising treatment which administers high-dose melphalan directly into the liver whilst controlling systemic exposure and the associated side effects. We hope that this will have a meaningful impact on the quality of life of these patients.”

CHEMOSAT® treatment is currently available at three key private centres in the UK, Spire Southampton Hospital, The Harley Street Clinic in London and The Christie Clinic, Manchester.

  • European Association of Urology (EAU)

    20 – 24 March 2020
    RAI, Amsterdam
    Urology

  • Anthony Nolan – Symposium – Innovative Cell Therapies

    20 March 2020
    Royal College of Physicians, London
    Haematology

  • EMBT – European Bone Marrow Transplantation

    22 – 25 March 2020
    IFEMA, Madrid
    Haematology

  • BSR – British Society of Rheumatology

    20 – 22 April 2020
    SEC, Glasgow
    Rheumatology

  • Melanoma Focus

    15 May 2020
    Leonardo Royal Southampton Grand Harbour Hotel, Southampton
    Oncology

  • NMIBC Workshops: Intravesical therapies – Glasgow

    1 June 2020
    Hilton Doubletree Glasgow Central, Glasgow
    Reserve your place.

  • NMIBC Workshops: Intravesical therapies – Guildford

    2 June 2020
    The Stokes Centre for Urology, Guildford
    Reserve your place.

  • SOPPG – Scottish Oncology Pharmacy Practice Group

    06 June 2020
    Doubletree Hilton, Dunblane
    Oncology

  • EULAR – European League Against Rheumatism

    03 – 06 June 2020
    MESSE, Frankfurt
    Rheumatology

  • Oncology Forum

    11 – 12 June 2020
    ICC, Birmingham
    Oncology

  • BAUS – British Association of Urology Surgeons

    15 – 17 June 2020
    BAUS, Birmingham
    Urology

  • BAD – British Association of Dermatology

    07 – 09 June 2020
    ACC, Liverpool
    Dermatology

  • NMIBC Workshops: Intravesical therapies – An update on theory and practice

    Register your interest.

  • Treatments of liver metastases: An update on practice for oncologists

    Register your interest.